During the last session, Sonnet BioTherapeutics Holdings Inc (NASDAQ:SONN)’s traded shares were 0.32 million, with the beta value of the company hitting 0.50. At the end of the trading day, the stock’s price was $1.75, reflecting an intraday gain of 9.37% or $0.15. The 52-week high for the SONN share is $18.72, that puts it down -969.71 from that peak though still a striking 19.43% gain since the share price plummeted to a 52-week low of $1.41. The company’s market capitalization is $5.26M, and the average intraday trading volume over the past 10 days was 0.22 million shares, and the average trade volume was 1.34 million shares over the past three months.
Sonnet BioTherapeutics Holdings Inc (SONN) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. SONN has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it.
Sonnet BioTherapeutics Holdings Inc (NASDAQ:SONN) trade information
Sonnet BioTherapeutics Holdings Inc (SONN) registered a 9.37% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 9.37% in intraday trading to $1.75, hitting a weekly high. The stock’s 5-day price performance is 17.45%, and it has moved by -27.39% in 30 days. Based on these gigs, the overall price performance for the year is -87.21%. The short interest in Sonnet BioTherapeutics Holdings Inc (NASDAQ:SONN) is 40115.0 shares and it means that shorts have 0.03 day(s) to cover.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 85.27%. While earnings are projected to return 69.87% in 2025.
SONN Dividends
Sonnet BioTherapeutics Holdings Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Sonnet BioTherapeutics Holdings Inc (NASDAQ:SONN)’s Major holders
Sonnet BioTherapeutics Holdings Inc insiders own 1.38% of total outstanding shares while institutional holders control 0.20%, with the float percentage being 0.20%.
